Lin Chen

Title: Lin Chen: Innovator in Oncolytic Adenovirus Research

Introduction

Lin Chen is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of oncolytic adenoviruses for cancer treatment. With a total of 4 patents, his work focuses on innovative therapeutic agents that target tumors and cancers.

Latest Patents

Lin Chen's latest patents include groundbreaking research on isolated recombinant oncolytic adenoviruses and their pharmaceutical compositions. One of his notable inventions provides an isolated recombinant oncolytic adenovirus that selectively replicates in tumor cells. This adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of this virus in normal primary cells is significantly lower than in tumor cells, enhancing its therapeutic potential. Additionally, the expressed shPDL1 can effectively reduce the level of PDL1 protein in tumor cells, leading to a synergistic effect between the oncolytic virus and immune cells.

Career Highlights

Throughout his career, Lin Chen has worked with various companies, including Hangzhou Converd Co., Ltd. His innovative research has positioned him as a key figure in the biotechnology sector, particularly in the development of cancer therapies.

Collaborations

Lin Chen has collaborated with notable professionals in his field, including Ronghua Zhao and Fang Hu. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Lin Chen's contributions to the field of oncolytic adenoviruses represent a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire progress in biotechnology.